Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50 (PDF)
(Sprache: Englisch)
New viruses can arise very quickly and, if unchecked, result in major pandemics. Obvious examples being the AIDS and SARS virus. In order to deal with such imminent threats, drug development times need to be cut short. This is only possible by relying on...
sofort als Download lieferbar
eBook (pdf)
Fr. 170.00
inkl. MwSt.
- Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50 (PDF)“
New viruses can arise very quickly and, if unchecked, result in major pandemics. Obvious examples being the AIDS and SARS virus. In order to deal with such imminent threats, drug development times need to be cut short. This is only possible by relying on proven strategies and adapting them to the specific features of any new virus or virus variant.
By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It is edited by Erik de Clercq, a world authority on antiviral drug discovery.
The volume covers a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases, and primases, as well as their known inhibitors. The book also contains several case studies of recent successful antiviral drug development.
As a result, medicinal and pharmaceutical chemists, as well as virologists will be able to pinpoint strategies for combating future viral pandemics.
By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It is edited by Erik de Clercq, a world authority on antiviral drug discovery.
The volume covers a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases, neuraminidases, RNA polymerases, helicases, and primases, as well as their known inhibitors. The book also contains several case studies of recent successful antiviral drug development.
As a result, medicinal and pharmaceutical chemists, as well as virologists will be able to pinpoint strategies for combating future viral pandemics.
Inhaltsverzeichnis zu „Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50 (PDF)“
Outlook of the Antiviral Drug Era, now more than 50 Years after Description of the First Antiviral Drug Inhibition of HIV Entry Targeting Integration Beyond Strand Transfer. Development of Second Generation HIV Integrase Inhibitors From Saquinavir to Darunavir, the Impact of 10 Years of Medicinal Chemistry on a Lethal Disease Acyclic and Cyclic Nucleoside Phosphonates Helicase-Primase Inhibitors - A New Approach to Combat Herpes Simplex Virus and Varicella-Zoster Virus Cyclophilin Inhibitors Alkoxyalkyl Ester Prodrugs of Antiviral Nucleoside Phosphates and Phosphonates Maribavir: A Novel Benzimidazole Ribonucleoside for the Prevention and Treatment of Cytomegalovirus Diseases Anti-HCMV Compounds Lethal Mutagenesis as an Unconventional Approach to Combat HIV Recent Progess in the Development of HCV Protease Inhibitors Antiviral RNAi, How to Silence Viruses Neuraminidase Inhibitors as Anti-Influenza Agents From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Autoren-Porträt
Erik De Clercq, M.D., PhD is currently President of the Rega Foundation, a member of the Belgian (Flemish) Royal Academy of Medicine and of the Academia Europaea, and a Fellow of the American Association for the Advancement of Science. He is an active Emeritus Professor of the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. He is honorary doctor of the Universities of Ghent, Belgium, Athens, Greece, Ferrara, Italy, Jinan (Shandong), China, Charles (Prague), Czech Republic, and Jihoceska (Ceské Budejovice), Czech Republic, and Tours, France.For his pioneering efforts in antiviral research, Professor De Clercq received in 1996 the Aventis award from the American Society for Microbiology, and in 2000 the Maisin Prize for Biomedical Sciences from the Belgian National Science Foundation. In 2008 he was elected Inventor of the Year by the European Union. Jointly with Dr. Anthony Fauci, Prof. De Clercq received the Dr. Paul Janssen Award for Biomedical Research in 2010.
He is the (co)inventor of a number of antiviral drugs, used for the treatment of HSV (valaciclovir, Valtrex , Zelitrex ), VZV (brivudin, Zostex , Brivirac , Zerpex ), CMV (cidofovir, Vistide ), HBV (adefovir dipivoxil, Hepsera ), and HIV infections (AIDS) (tenofovir disoproxil fumarate, Viread ).
Bibliographische Angaben
- 2011, 1. Auflage, 406 Seiten, Englisch
- Herausgegeben: Erik De Clercq
- Verlag: Wiley-VCH GmbH
- ISBN-10: 3527635971
- ISBN-13: 9783527635979
- Erscheinungsdatum: 17.03.2011
Abhängig von Bildschirmgrösse und eingestellter Schriftgrösse kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Grösse: 7.35 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50"
0 Gebrauchte Artikel zu „Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Antiviral Drug Strategies / Methods and Principles in Medicinal Chemistry Bd.50".
Kommentar verfassen